Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Hypericin

    DEVELOPMENTS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HyBryte™ Clinical Results Show Continued Post-Treatment Improvement
    HyBryte™ Clinical Results Show Continued Post-Treatment Improvement

    02 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hybryte-clinical-results-demonstrate-continued-improvement-post-treatment-302317457.html

    PR NEWSWIRE
    02 Dec 2024
    Share Share
    Expanded HyBryte Shows Positive Results In Early-Stage Lymphoma
    Expanded HyBryte Shows Positive Results In Early-Stage Lymphoma

    09 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/expanded-hybryte-treatment-demonstrating-positive-outcomes-in-early-stage-cutaneous-t-cell-lymphoma-302190262.html

    PR NEWSWIRE
    09 Jul 2024
    Share Share
    Soligenix stock sinks as FDA refuses lymphoma application
    Soligenix stock sinks as FDA refuses lymphoma application

    15 Feb 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/soligenxs-stock-sinks-36-after-fda-refuses-consider-lymphoma-therapy-application

    James Waldron FIERCE BIOTECH
    15 Feb 2023
    Share Share
    Soligenix opens patient enrolment for Phase IIa trial of psoriasis therapy
    Soligenix opens patient enrolment for Phase IIa trial of psoriasis therapy

    19 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/soligenix-patient-enrolment-trial-psoriasis/

    CLINICALTRIALSARENA
    19 Dec 2022
    Share Share
    Soligenix opens patient enrolment for Phase IIa trial of psoriasis therapy
    Soligenix opens patient enrolment for Phase IIa trial of psoriasis therapy

    19 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/soligenix-patient-enrolment-trial-psoriasis/

    CLINICALTRIALSARENA
    19 Dec 2022
    Share Share
    FDA Clears Soligenix's IND for PII Trial of Synthetic Hypericin in Psoriasis
    FDA Clears Soligenix's IND for PII Trial of Synthetic Hypericin in Psoriasis

    28 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-receives-fda-ind-clearance-for-phase-2-clinical-trial-of-synthetic-hypericin-in-the-treatment-of-psoriasis-301575751.html

    PRNEWSWIRE
    28 Jun 2022
    Share Share